B

Bio-Path Holdings

D
BPTH
USD
0.001
(0.1149%)
Market Closed
1,054.00
Volume
-8.07
EPS
-
Div Yield
-0.061381
P/E
2,222,957.49
Market Cap
Today
-6.3441%
1 Week
-6.384%
1 Month
2.471%
6 Months
-70.967%
12 Months
-92.742%
Year To Date
-90.925%
All Time
0%

Title:
Bio/Path Holdings

Sector:
Healthcare
Industry:
Biotechnology
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition forany gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Do you need help or have a question?